Daniel Prieto-Alhambra

Oct 25, 2024 | jamanetwork.com | Daniel Prieto-Alhambra

Introduction Chronic multisystem manifestations of SARS-CoV-2 infection (ie, post–COVID-19 condition [PCC]) are a specific type of postacute infection syndrome (PAIS) that can occur after other lower respiratory tract infections (LRTIs) but are often overlooked.1 Research on PAIS primarily captures it through inpatient diagnoses, missing milder cases and those not seeking care.2 We performed pairwise comparisons of patient-reported, multisystem, postacute symptoms among individuals...

Sep 4, 2024 | onlinelibrary.wiley.com | John Tazare |Shirley Wang |Rosa Gini |Daniel Prieto-Alhambra

This study aimed to quantify current trends of programming code sharing in pharmacoepidemiology research and provide recommendations on this topic. Out of 968 eligible “Pharmacoepidemiology and Drug Safety” articles between 2017 and 2022, 4.8% (N = 46) shared programming code. Code sharing increased from 1.8% in 2017 to 9.5% in 2022, with higher prevalence in methodological and simulation studies.

Jun 26, 2024 | jclinepi.com | Danielle Robinson |Antonella Delmestri |Andrew Clegg |Leena Elhussein |Daniel Prieto-Alhambra |Alan J Silman

This paper is only available as a PDF. To read, Please Download here. HighlightsWhat is new? Key findings•We identified five subgroups of older people with different frailty progression patterns and associated risk of death. These subgroups had distinct patterns of frailty progression over four years based on the changes in electronic Frailty Index (eFI) score. What this adds to what was known? •eFI is being used in UK primary care to identify vulnerable older people using one cross-sectional value.

Apr 10, 2024 | thelancet.com | Angela Lupattelli |Daniel Prieto-Alhambra

Our recent study using data from more than 20 million participants has shown that COVID-19 vaccines consistently prevent long COVID symptoms in adults, with meta-analytic calibrated subdistribution hazard ratio (sHRs) of 0·54 (95% CI 0·44–0·67) in CPRD GOLD, 0·48 (0·34–0·68) in CPRD AURUM, 0·71 (0·55–0·91) in SIDIAP, and 0·59 (0·40–0·87) in CORIVA. 1Català M Mercadé-Besora N Kolde R et al.

Mar 15, 2024 | medrxiv.org | Daniel Prieto-Alhambra |Francesco Dernie |Antonella Delmestri |Trishna Rathod-Mistry

DPA 's department has received grant/s from Amgen, Chiesi-Taylor, Lilly, Janssen, Novartis, and UCB Biopharma. His research group has received consultancy fees from Astra Zeneca and UCB Biopharma. Amgen, Astellas, Janssen, Synapse Management Partners and UCB Biopharma have funded or supported training programmes organised by DPA's department. All other authors declare no conflict.